Given that BCR-ABL1 activates Myc transcription and increases the inactivating phosphorylation of FOXO1 in this B-ALL model [7], we treated the cells with 1 μM of the BCR-ABL1 inhibitor imatinib to abolish Myc expression. Here, MYC is linked to acute lymphoblastic leukemia.